China NMPA Drug Inspection - Lanzhou Xukang Pharmaceutical Co., Ltd. - mugwort

On January 29, 2022, the Gansu Provincial Drug Administration, operating under the National Medical Products Administration (NMPA) framework, released an official quality announcement regarding the first phase of drug sampling inspections for 2022. The inspections, conducted by five professional testing institutions including the Lanzhou Municipal Institute for Food and Drug Control, identified eight batches of medicinal products that failed to meet mandatory quality standards. One of the primary companies cited in the report is Lanzhou Xukang Pharmaceutical Co., Ltd., which was among six manufacturers involved in the production of substandard items. A notable product mentioned in the findings was Artemisia argyi, a traditional medicinal herb. The violations center on the failure to adhere to established pharmaceutical quality benchmarks. In response to these findings, the regulatory authorities have mandated immediate risk control measures for the affected batches. The involved companies and units are required to handle the substandard products in strict accordance with national drug laws and regulations. This action emphasizes the administration's role in ensuring public safety by monitoring the pharmaceutical supply chain and enforcing compliance through rigorous testing and public disclosure of non-conformities.